ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside pipeline advances at CROI 2021
For media and investors only |
Data presented will demonstrate the potential of new antiretroviral mechanisms of action and long-acting medicines that challenge the HIV treatment and prevention paradigm
London, 2 March 2021 - ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the presentation of 16 sponsored abstracts from its diverse portfolio of innovative pipeline and licensed HIV treatment and prevention options at the Conference on Retroviruses and Opportunistic Infections (CROI 2021), being held virtually 6-10 March.
Key data presentations will include:
• ATLAS-2M 96-week findings for investigational long-acting cabotegravir and rilpivirine administered every 2-months for the treatment of HIV-1 in virologically suppressed adults, which build upon earlier 48-week efficacy and safety data, as well as an analysis of renal and bone outcomes from ATLAS and ATLAS-2M.[i]
Kimberly Smith, M.D., MPH, Head of Research & Development at ViiV Healthcare, said: "The innovation powered by our research and development team strives to redefine what is possible in both HIV treatment and prevention. The findings that will be presented at CROI 2021 reflect this goal, with new data that further establish our leadership in long-acting therapies for HIV treatment and prevention, as well as proof-of-concept data from our early pipeline that explore a new mechanism of action maturation inhibitor. We look forward to sharing these findings during CROI 2021 with the HIV community."
• Phase IIa proof-of-concept findings for the maturation inhibitor GSK3640254 (GSK'254), a novel, investigational, antiretroviral agent with a new mechanism of action that is being studied in adults living with HIV-1.[ii]
• Pharmacokinetic (PK) and resistance data from HPTN 083,* a study of investigational cabotegravir every 2-months for HIV prevention from HPTN 083 in men who have sex with men (MSM) and transgender women (TGW).[iii]
Key abstracts to be presented by ViiV Healthcare and study partners at CROI 2021:
Week 96 findings from the ATLAS-2M study evaluating investigational long-acting cabotegravir and rilpivirine administered every 2-months compared to once-monthly for the treatment of HIV-1: The ATLAS-2M study was designed to assess the non-inferiority and safety of long-acting cabotegravir and rilpivirine administered every 2-months compared to its once-monthly administration for treatment of HIV-1.[iv] The two-year findings to be presented at CROI 2021 will include cabotegravir and rilpivirine's efficacy, safety and tolerability data, consistent with the previous 48-week data presentation.[v]
Week 48 renal and bone outcomes from investigational long-acting cabotegravir and rilpivirine administered every 2-months and once-monthly across ATLAS and ATLAS-2M for the treatment of HIV-1: The phase III development program of long-acting cabotegravir and rilpivirine was designed to demonstrate the regimen's efficacy and safety when dosed once-monthly in ATLAS and every 2-months in ATLAS-2M for HIV treatment. Findings to be presented at CROI 2021 will provide further insights into renal and bone-specific outcomes among study participants.
PK and resistance data from the global HPTN 083* study evaluating cabotegravir as an investigational HIV prevention drug: The HPTN 083 study was designed to compare the efficacy and safety of every 2-month, long-acting, injectable cabotegravir to daily oral PrEP among MSM and TGW. Findings to be presented at CROI 2021 will provide additional information about seroconverters, PK, and resistance.4
Proof-of-concept findings from the phase IIa study of the maturation inhibitor GSK3640254 (GSK'254): The phase IIa proof-of-concept study was designed to evaluate the antiviral activity, safety, and tolerability of the once-daily maturation inhibitor GSK'254 in adults living with HIV-1.[vi] Findings to be presented at CROI 2021 will provide support for the continued study of this innovative investigational antiretroviral agent.5
The full list of ViiV Healthcare data to be presented at CROI 2021 is outlined below:
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012. The company's aims are to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.
For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com.
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit https://www.gsk.com/en-gb/about-us.
Media enquiries: Melinda Stubbee
Sofia Kalish +1 919 491 0831
+44 (0) 7341 079531 (North Carolina)
Audrey Abernathy +1 919 605 4521 (North Carolina)
Media enquiries: Simon Steel +44 (0) 20 8047 5502 (London)
Tim Foley +44 (0) 20 8047 5502 (London)
Kristen Neese +1 804 217 8147 (Philadelphia)
Kathleen Quinn +1 202 603 5003 (Washington DC)
Analyst/Investor enquiries: Sarah Elton-Farr +44 (0) 20 8047 5194 (London)
Sonya Ghobrial +44 (0) 7392 784784 (Consumer)
James Dodwell +44 (0) 20 8047 2406 (London)
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Frannie DeFranco +1 215 751 4855 (Philadelphia)
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk Factors" in the company's Annual Report on Form 20-F for 2019 and any impacts of the COVID-19 pandemic.
[i] Jaeger H, Overton E, Richmond G, et al. Week 96 efficacy and safety of cabotegravir + rilpivirine every 2 months: ATLAS-2M. Presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2021.
[ii] Spinner C, Felizarta F, Rizzardini G, et al. Phase IIa proof-of-concept trial of next-generation maturation inhibitor GSK3640254. Presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2021.
[iii] Marzinke M, Grinsztejn B, Fogel J, et al. Laboratory analysis of HIV infections in HPTN 083: Injectable cabotegravir (CAB) vs daily, oral TDF/FTC for PrEP in MSM/TGW. Presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2021.
[iv] Study evaluating the efficacy, safety, and tolerability of long-acting cabotegravir plus long-acting rilpivirine administered every 8 weeks in virologically suppressed HIV-1-infected adults. Available at: https://clinicaltrials.gov/ct2/show/NCT03299049. Last accessed September 2020.
[v] Overton E, Richmond G, Rizzardini G, et al. Cabotegravir + rilpivirine every 2 months is noninferior to monthly. ATLAS-2M study. Presented at Conference on Retroviruses and Opportunistic Infections (CROI) March 2020.
[vi] Clinical trials.gov. A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults. Available at: https://clinicaltrials.gov/ct2/show/NCT03784079. Accessed March 2021.